Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients

Mark Hyman Rapaport, Owen Wolkowitz, John R. Kelsoe, Carlos Pato, P. Eric Konicki, David Pickar

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


It was postulated that chronic blockade of the opioid system in neuroleptic-stabilized schizophrenic patients would have a beneficial behavioral effect. Eleven neuroleptic-stabilized psychotic inpatients received augmentation with nalmefene for an average of 36.7 days in a double-blind placebo-controlled study. The patients exhibited significant reductions in Bunney-Hamburg psychosis ratings and the Brief Psychiatric Rating Scale thinking disturbance subscale during the augmentation period. This study presents preliminary data supporting the hypothesis that chronic augmentation of neuroleptic-stabilized schizophrenic patients with opiate antagonists is beneficial.

Original languageEnglish (US)
Pages (from-to)111-115
Number of pages5
Issue number2
StatePublished - 1993
Externally publishedYes


  • Neuroleptics
  • Opiate antagonists
  • Opiates
  • Psychotropic treatment
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients'. Together they form a unique fingerprint.

Cite this